K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · BRISTOL-MYERS SQUIBB COMPANY
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | BMY | BRISTOL-MYERS SQUIBB COMPANY | BRISTOL-MYERS SQUIBB COMPANY | $1.3M | H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.7391, CHC Drug Pricing Protection Act H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation Intellectual Property Reform concerning bio-pharmaceutical industry International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues |
| 2026-04-20 | BMY | BRISTOL-MYERS SQUIBB COMPANY | WILLIAMS AND JENSEN, PLLC | $80K | 340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation. Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues. H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies. |
| 2026-04-20 | BMY | BRISTOL-MYERS SQUIBB COMPANY | AVENUE SOLUTIONS | $60K | Issues related to prescription drugs Issues related to prescription drugs; Issues related to Senate Finance Dear Colleague process |
| 2026-04-20 | BMY | BRISTOL-MYERS SQUIBB COMPANY | TODD STRATEGY GROUP | $50K | Biosimilars reimbursement issues. Supply Chain Issues. Pharmacy Benefit Manager Reform. Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program. |
| 2026-04-20 | BMY | BRISTOL-MYERS SQUIBB COMPANY | W STRATEGIES, LLC | $30K | Education about the value of biopharmaceutical innovation and related issues. |
| 2026-04-20 | BMY | BRISTOL-MYERS SQUIBB COMPANY | MILLER STRATEGIES, LLC | $0 | Issues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform. Issues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform. |
| 2026-04-17 | BMY | BRISTOL-MYERS SQUIBB COMPANY | MARSHALL & POPP, LLC | $40K | Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. |
| 2026-02-24 | BMY | BRISTOL-MYERS SQUIBB COMPANY | MARSHALL & POPP, LLC | $0 | Issues related to pharmaceutical manufacuring. Drug pricing. Trade and tariffs. Issues related to pharmaceutical manufacuring. Drug pricing. Trade and tariffs. |
| 2026-02-23 | BMY | BRISTOL-MYERS SQUIBB COMPANY | AVENUE SOLUTIONS | $0 | Issues related to prescription drugs. Issues related to prescription drugs. |
| 2026-02-18 | BMY | BRISTOL-MYERS SQUIBB COMPANY | W STRATEGIES, LLC | $0 | Education about the value of biopharmaceutical innovation and related issues. |
| 2026-01-20 | BMY | BRISTOL-MYERS SQUIBB COMPANY | BRISTOL-MYERS SQUIBB COMPANY | $1.3M | H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation Intellectual Property Reform concerning bio-pharmaceutical industry International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues |
| 2026-01-20 | BMY | BRISTOL-MYERS SQUIBB COMPANY | WILLIAMS AND JENSEN, PLLC | $80K | 340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation. Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues. H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies. |
| 2026-01-20 | BMY | BRISTOL-MYERS SQUIBB COMPANY | TODD STRATEGY GROUP | $50K | Biosimilars reimbursement issues. Supply Chain Issues. Pharmacy Benefit Manager Reform. Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program. |
| 2026-01-20 | BMY | BRISTOL-MYERS SQUIBB COMPANY | MILLER STRATEGIES, LLC | $0 | Issues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform. Issues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform. |
| 2025-10-20 | BMY | BRISTOL-MYERS SQUIBB COMPANY | BRISTOL-MYERS SQUIBB COMPANY | $3.2M | H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act Discussions regarding H.R.1, One Big Beautiful Bill Act regarding bio-pharmaceutical provisions Biosimilars reimbursement issues H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.1968, lobbied for passage of the Continuing Resolution to include PBM reform Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act Issues related to the six protected classes of medicines under Medicare Part D, regarding all bio-pharmaceutical issues Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation Intellectual Property Reform concerning bio-pharmaceutical industry S.864, HELP Copays Act S.526, Pharmacy Benefit Manager Transparency Act of 2025 H.R.3285, Fairne |
| 2025-10-20 | BMY | BRISTOL-MYERS SQUIBB COMPANY | WILLIAMS AND JENSEN, PLLC | $50K | 340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation. Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues. H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies. |
| 2025-10-20 | BMY | BRISTOL-MYERS SQUIBB COMPANY | TODD STRATEGY GROUP | $50K | Biosimilars reimbursement issues. Supply Chain Issues. Pharmacy Benefit Manager Reform. Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program. |
| 2025-10-20 | BMY | BRISTOL-MYERS SQUIBB COMPANY | MILLER STRATEGIES, LLC | $30K | Issues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform. Issues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform. |
| 2025-10-06 | BMY | BRISTOL-MYERS SQUIBB COMPANY | MILLER STRATEGIES, LLC | $0 | Issues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform. Issues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform. |
| 2025-09-17 | BMY | BRISTOL-MYERS SQUIBB COMPANY | WILLIAMS AND JENSEN, PLLC | $0 | Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, 340B reform, FDA drug approval. Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, 340B reform, FDA drug approval. Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, 340B reform, FDA drug approval. Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, 340B reform, FDA drug approval. |
| 2025-07-21 | BMY | BRISTOL-MYERS SQUIBB COMPANY | BRISTOL-MYERS SQUIBB COMPANY | $4.8M | H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act Discussions regarding H.R.1, One Big Beautiful Bill Act regarding bio-pharmaceutical provisions Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions Issues related to the six protected classes of medicines under Medicare Part D, regarding all bio-pharmaceutical issues Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation Intellectual Property Reform concerning bio-pharmaceutical industry S.864, HELP Copays Act S.526, Pharmacy Benefit Manager Transparency Act of 2025 H.R.3285, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act Modernizing and Ensuring Equity Act H.R.3521, Clinical Trials Modernization Act Discussions regarding Continuing Resolution to include PBM reform, H.R.1968 Intern |
| 2025-07-19 | BMY | BRISTOL-MYERS SQUIBB COMPANY | TODD STRATEGY GROUP | $50K | Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program. Biosimilars reimbursement issues. Supply Chain Issues. Pharmacy Benefit Manager Reform. |
| 2025-04-21 | BMY | BRISTOL-MYERS SQUIBB COMPANY | TODD STRATEGY GROUP | $50K | Biosimilars reimbursement issues. Supply Chain Issues. Pharmacy Benefit Manager Reform. Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program |
| 2025-04-20 | BMY | BRISTOL-MYERS SQUIBB COMPANY | BRISTOL-MYERS SQUIBB COMPANY | $870K | Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 MINI Act ORPHAN Act Mental Health Appropriations Language FY26 Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation Intellectual Property Reform concerning bio-pharmaceutical industry H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring Equity Act H.R.8412, Clinical Trials Modernization Act |
| 2025-01-21 | BMY | BRISTOL-MYERS SQUIBB COMPANY | BRISTOL-MYERS SQUIBB COMPANY | $790K | Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 MINI Act Biosimilars reimbursement issues Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Intellectual Property Reform concerning bio-pharmaceutical industry Discussions regarding the Patent Eligibility Restoration Act H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 202 |
| 2025-01-21 | BMY | BRISTOL-MYERS SQUIBB COMPANY | TODD STRATEGY GROUP | $50K | Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. Biosimilars reimbursement issues. Supply Chain Issues. |